THERAtRAME

tolremo

This company develops small molecule drugs to prevent non-genetic resistance in cancer patients receiving targeted therapies.

KyDo Therapeutics

This company develops covalent-allosteric small molecule inhibitors for the treatment of challenging cancer variants within the oncology sector.

ARase Therapeutics

This company develops small molecule drugs targeting ADP-ribose hydrolases for patients with various forms of cancer.

Cold Start Therapeutics

This company develops multimeric fusion proteins using machine learning to target cancer cells and engage immune cells for patients with oncological diseases.

TwoStep Therapeutics

The company develops peptide-drug conjugates and targeted therapies for patients with solid tumours.

Type6 Therapeutics

This deep-tech company develops kinase inhibitors for cancer treatment, intercepting enzymes in their inactive states to address drug resistance for patients with aggressive tumours.

UPPTHERA

The company develops targeted protein degradation therapies for patients with cancer and rare diseases and provides platform technologies to pharmaceutical and biotechnology companies.

Typewriter Therapeutics

The company develops RNA-based genetic medicines for patients with cancer, autoimmune conditions and rare genetic diseases.